Baldanti F, Underwood M R, Stanat S C, Biron K K, Chou S, Sarasini A, Silini E, Gerna G
Viral Diagnostic Service, IRCCS Policlinico S. Matteo, University of Pavia, Italy.
J Virol. 1996 Mar;70(3):1390-5. doi: 10.1128/JVI.70.3.1390-1395.1996.
Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A. Sarasini, F. Baldanti, M. Furione, E. Percivalle, R. Brerra, M. Barbi, and G. Gerna, J. Med. Virol., 47:237-244, 1995). We previously demonstrated that the three strains were genetically unrelated and that each of them was present as a single viral population in vivo. Thus, in each of the three cases, a single viral strain was resistant to both GCV and PFA. In the present paper, we report the characterization of the molecular bases of the double resistance and demonstrate that the PFA resistance is associated with a slower replication of HCMV strains in cell cultures. Sequencing of the UL97 and UL54 genes, GCV anabolism assays, and marker transfer experiments showed that GCV resistance was due to single amino acid changes in the UL97 gene product (VR4760, Met-460 --> Ile; VR4955, Ala-594 --> Val; VR5120, Leu595 --> Ser), while single amino acid changes in domain II of the DNA polymerase (VR4760 and VR5120, Val-715 --> Met; VR4955, Thr-700 --> Ala) were responsible for both the PFA resistance and the slow-growth phenotype. Thus, in these three cases, double resistance to GCV and PFA was not due to a single mutation conferring cross-resistance or to the presence of a mixture of strains with different drug susceptibilities. The HCMV DNA polymerase recombinant strains carrying the mutations conferring PFA resistance were sensitive to GCV and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). In addition, the same UL54 mutations were responsible for the slow growth of the clinical isolates, since the recombinant strains showed a marked delay in immediate-early antigen plaque formation and a reduction of infectious virus yield compared with AD169, from which they were derived. These results may have some important implications for the successful isolation, propagation, and characterization of PFA-resistant strains from clinical samples containing mixed viral populations.
从三名接受更昔洛韦(GCV)和膦甲酸钠(PFA)多轮序贯治疗的艾滋病患者中分离出三株对GCV和PFA均耐药的人巨细胞病毒(HCMV)毒株(VR4760、VR4955和VR5120)(A. Sarasini、F. Baldanti、M. Furione、E. Percivalle、R. Brerra、M. Barbi和G. Gerna,《医学病毒学杂志》,47:237 - 244,1995年)。我们之前证明这三株毒株在基因上无关联,且它们在体内均以单一病毒群体形式存在。因此,在这三个病例中,单一病毒株对GCV和PFA均耐药。在本文中,我们报告了双重耐药分子基础的特征,并证明PFA耐药与HCMV毒株在细胞培养中的复制较慢有关。UL97和UL54基因测序、GCV合成代谢分析以及标记转移实验表明,GCV耐药是由于UL97基因产物中的单个氨基酸变化(VR4760,Met - 460 --> Ile;VR4955,Ala - 594 --> Val;VR5120,Leu595 --> Ser),而DNA聚合酶结构域II中的单个氨基酸变化(VR4760和VR5120,Val - 715 --> Met;VR4955,Thr - 700 --> Ala)导致了PFA耐药和生长缓慢表型。因此,在这三个病例中,对GCV和PFA的双重耐药并非由于赋予交叉耐药性的单一突变或存在具有不同药物敏感性的毒株混合物。携带赋予PFA耐药性突变的HCMV DNA聚合酶重组毒株对GCV和(S) - 1 - (3 - 羟基 - 2 - 膦酰甲氧基丙基)胞嘧啶(HPMPC)敏感。此外,相同的UL54突变导致了临床分离株的生长缓慢,因为与它们所衍生的AD169相比,重组毒株在早期抗原蚀斑形成方面明显延迟,且感染性病毒产量降低。这些结果对于从含有混合病毒群体的临床样本中成功分离、培养和鉴定PFA耐药毒株可能具有一些重要意义。